File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1139/y85-133
- Scopus: eid_2-s2.0-0022404647
- PMID: 4042015
- WOS: WOS:A1985ANY9400006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The effect of lidocaine on lysophosphatidylcholine-induced cardiac arrhythmias and cellular disturbances
Title | The effect of lidocaine on lysophosphatidylcholine-induced cardiac arrhythmias and cellular disturbances |
---|---|
Authors | |
Issue Date | 1985 |
Publisher | N R C Research Press. The Journal's web site is located at http://pubs.nrc-cnrc.gc.ca/cgi-bin/rp/rp2_desc_e?cjpp |
Citation | Canadian Journal Of Physiology And Pharmacology, 1985, v. 63 n. 7, p. 804-808 How to Cite? |
Abstract | The production of arrhythmias in the isolated heart by perfusion with lysophosphatidylcholine has been well documented. However, the role of the lysophospholipid as a physiological factor in the generation of cardiac arrhythmias is not clear. In this study, a pharmacological approach was used to delineate the physiological significance of lysophosphatidylcholine during this cardiac dysfunction. Lidocaine (5-20 mg/L) was found to be effective in the protection of the isolated rat heart from the lysophospholipid-induced arrhythmias at pharmacological concentrations. The effect of lidocaine in the protection of lysophospholipid-induced membrane dysfunction was studied with red blood cells. Lidocaine (2 mg/L) protected red blood cells from hemolysis in the presence of lysophosphatidylcholine. Lidocaine did not inhibit the binding of the lysophospholipid to the red cell membrane, but inhibited hemolysis in a manner similar to cholesterol. The results are consistent with the postulate that lysophosphatidylcholine is a physiological factor in the pathogenesis of cardiac arrhythmias during myocardial ischemia. |
Persistent Identifier | http://hdl.handle.net/10722/170802 |
ISSN | 2023 Impact Factor: 1.7 2023 SCImago Journal Rankings: 0.499 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Neufeld, KJ | en_US |
dc.contributor.author | Lederman, CL | en_US |
dc.contributor.author | Choy, PC | en_US |
dc.contributor.author | Man, RYK | en_US |
dc.date.accessioned | 2012-10-30T06:10:55Z | - |
dc.date.available | 2012-10-30T06:10:55Z | - |
dc.date.issued | 1985 | en_US |
dc.identifier.citation | Canadian Journal Of Physiology And Pharmacology, 1985, v. 63 n. 7, p. 804-808 | en_US |
dc.identifier.issn | 0008-4212 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/170802 | - |
dc.description.abstract | The production of arrhythmias in the isolated heart by perfusion with lysophosphatidylcholine has been well documented. However, the role of the lysophospholipid as a physiological factor in the generation of cardiac arrhythmias is not clear. In this study, a pharmacological approach was used to delineate the physiological significance of lysophosphatidylcholine during this cardiac dysfunction. Lidocaine (5-20 mg/L) was found to be effective in the protection of the isolated rat heart from the lysophospholipid-induced arrhythmias at pharmacological concentrations. The effect of lidocaine in the protection of lysophospholipid-induced membrane dysfunction was studied with red blood cells. Lidocaine (2 mg/L) protected red blood cells from hemolysis in the presence of lysophosphatidylcholine. Lidocaine did not inhibit the binding of the lysophospholipid to the red cell membrane, but inhibited hemolysis in a manner similar to cholesterol. The results are consistent with the postulate that lysophosphatidylcholine is a physiological factor in the pathogenesis of cardiac arrhythmias during myocardial ischemia. | en_US |
dc.language | eng | en_US |
dc.publisher | N R C Research Press. The Journal's web site is located at http://pubs.nrc-cnrc.gc.ca/cgi-bin/rp/rp2_desc_e?cjpp | en_US |
dc.relation.ispartof | Canadian Journal of Physiology and Pharmacology | en_US |
dc.subject.mesh | Albumins - Pharmacology | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Arrhythmias, Cardiac - Chemically Induced - Physiopathology - Prevention & Control | en_US |
dc.subject.mesh | Cell Membrane - Drug Effects | en_US |
dc.subject.mesh | Cholesterol - Pharmacology | en_US |
dc.subject.mesh | Electrocardiography | en_US |
dc.subject.mesh | Erythrocyte Membrane - Metabolism | en_US |
dc.subject.mesh | Hemolysis - Drug Effects | en_US |
dc.subject.mesh | Lidocaine - Pharmacology | en_US |
dc.subject.mesh | Lysophosphatidylcholines - Antagonists & Inhibitors - Toxicity | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Ventricular Fibrillation - Blood | en_US |
dc.title | The effect of lidocaine on lysophosphatidylcholine-induced cardiac arrhythmias and cellular disturbances | en_US |
dc.type | Article | en_US |
dc.identifier.email | Man, RYK:rykman@hkucc.hku.hk | en_US |
dc.identifier.authority | Man, RYK=rp00236 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1139/y85-133 | - |
dc.identifier.pmid | 4042015 | - |
dc.identifier.scopus | eid_2-s2.0-0022404647 | en_US |
dc.identifier.volume | 63 | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.spage | 804 | en_US |
dc.identifier.epage | 808 | en_US |
dc.identifier.isi | WOS:A1985ANY9400006 | - |
dc.publisher.place | Canada | en_US |
dc.identifier.scopusauthorid | Neufeld, KJ=7003453938 | en_US |
dc.identifier.scopusauthorid | Lederman, CL=6701809777 | en_US |
dc.identifier.scopusauthorid | Choy, PC=7006633002 | en_US |
dc.identifier.scopusauthorid | Man, RYK=7004986435 | en_US |
dc.identifier.issnl | 0008-4212 | - |